CHARACTERISTICS OF SECONDARY PUBLICATIONS FROM RCTs ASSESSING EFFICACY AND SAFETY OF BIOLOGIC OR SMALL-MOLECULE TREATMENTS IN IMMUNE-MEDIATED INFLAMMATORY DISEASES

Summarise with VIRAT
Authors: Nguyễn Giang Hương Trần, Laurence Le Cleach, Robin Guelimi
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Reports from randomized controlled trials (RCTs) are highly praised for their high-quality evidence of the efficacy and safety of a new treatment or drug. The recommendation for RCT report by Consolidated Standards of Reporting Trials (CONSORT) 2010 emphasized that the main trial report should include “the results for all outcome analyses that were prespecified in the trial protocol or statistical analysis plan”. Nonetheless, it has been reported that results from one RCT were re-used, included in multiple testing or exploratory analysis, and “salami-sliced” – which indicates the fragmentation of findings from the main trial report – to produce multiple “secondary” RCTs publications, both separately or in combination with other RCTs’ results. Secondary publications with replicative and redundant results have been found common in some medical fields, including surgical and pediatric fields. Furthermore, secondary reports may be more likely to be published with advantageous results or statistically significant findings from multiple testing. As a result, selective outcome reporting bias may be present. Besides the possible bias, over-publishing secondary publications may cause waste in research efforts. The impact of potential waste and bias may even be more profound when conducting systematic reviews and meta-analyses of RCTs. Multiplicity, combined with insufficient or conflicting reporting about designs and results, may possibly increase the risk of including more than one report of one RCT when synthesizing evidence. Furthermore, “cherry-picking” outcome report - selecting favorable information among multiple publications of a trial to manipulate the results - can profoundly alter the conclusion about the intervention efficacy. Immune-mediated inflammatory diseases (IMIDs) comprise a group of heterogeneous conditions characterized by similar immune system mechanisms, in which the immune system mistakenly attacks healthy body cells. There has been a growing number of studies and publications evaluating new systemic therapies for these diseases, particularly focused on biologic and small-molecule therapies. Given the extent of salami-slicing and redundancy among literature, with evolving types over time, we aimed to explore the patterns, as well as the factors influencing the practice of secondary publication.

Fields of Study & Subjects

Meta-analysis and systematic reviews Pharmaceutical industry and healthcare Academic Publishing and Open Access

Publication details

Journal / source
OSF Preprints (OSF Preprints)
Publication date
1 October 2026
Language
EN
Document type
Preprint